Deep vein thrombosis of lower extremity: Direct intraclot injection of alteplase once daily with systemic anticoagulation - Results of pilot study

Radiology

Volumn 246, Issue 2, 2008, Pages 619-629

  Chang, Richard ^a   Chen, Clara C ^a   Kam, Anthony ^a   Mao, Edie ^a   Shawker, Thomas H ^a   Horne III, McDonald K ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANTIPLASMIN; D DIMER; FIBRINOGEN; HEMOGLOBIN; HEPARIN; PLASMINOGEN; WARFARIN; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ANGIOPLASTY; ANTICOAGULANT THERAPY; ARTICLE; BALLOON DILATATION; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPRESSION GARMENT; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; EMBOLISM; FEMALE; FEMORAL VEIN; FIBRINOGEN BLOOD LEVEL; FIBRINOLYTIC THERAPY; FOLLOW UP; FUNDING; HEMATOMA; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFORMED CONSENT; INTERNATIONAL NORMALIZED RATIO; LEG PAIN; LEG THROMBOSIS; LUNG EMBOLISM; LUNG PERFUSION; LUNG VENTILATION; MALE; MAY THURNER SYNDROME; MEDICAL SOCIETY; OPTIMAL DRUG DOSE; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL CIRCULATION; PERIPHERAL EDEMA; PILOT STUDY; POPLITEAL VEIN; POSTTHROMBOSIS SYNDROME; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; RECURRENT DISEASE; RISK ASSESSMENT; SCORING SYSTEM; STENT; SYNDROME; THROMBOCYTE COUNT; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; VASCULAR PATENCY; VEIN CATHETERIZATION; VEIN INSUFFICIENCY; ADOLESCENT; DRUG ADMINISTRATION; DRUG COMBINATION; INTRALESIONAL DRUG ADMINISTRATION; MIDDLE AGED; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGED; ANTICOAGULANTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MIDDLE AGED; PILOT PROJECTS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 39549083660     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2461062076     Document Type: Article

References (52)

1. Strandness D, Langlois Y, Cramer M, et al. Long-term sequelae of acute venous thrombosis. JAMA 1983;250:1289-1292.
2. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep vein thrombosis. Ann Intern Med 1996;125:1-7.
3. Prandoni P, Villalta S, Bagatella P, et al. The clinical course of deep vein thrombosis: prospective long term follow-up of 528 symptomatic patients. Haematologica 1997;82:423-428.
4. Thrombolytic therapy in thrombosis: a National Institutes of Health consensus development conference. Ann Intern Med 1980;93:141-144.
5. Saarinen J, Kallio T, Lehto M, Hiltunen S, Sisto T. The occurrence of the post-thrombotic changes after an acute deep vein thrombosis: a prospective 2 year follow-up study. J Cardiovasc Surg (Torino) 2000;41:441-446.
6. Lindner DJ, Edwards JM, Phinney ES, Taylor LM, Porter JM. Long term hemodynamic and clinical sequelae of lower extremity deep vein thrombosis. J Vasc Surg 1986;4:436-442.
7. Watz R, Savidge GF. Rapid thrombolysis and preservation of valvular venous function in high deep vein thrombosis. Acta Med Scand 1979;205:293-298.
8. Robertson BR, Nilsson IM, Nylander G. Value of streptokinase and heparin in therapy of acute deep vein thrombosis. Acta Chir Scand 1968;134:203-208.
9. Browse NL, Thomas ML, Pim HP. Streptokinase and deep vein thrombosis. Br Med J 1968;3:717-720.
10. Elliot MS, Immelman EJ, Jeffrey P, et al. A comparative randomized trial of heparin versus streptokinase in the treatment of acute proximal venous thrombosis: an interim report of a prospective trial. Br J Surg 1979;66:838-843.
11. Meissner MH, Manzo RA, Bergelin RO, Markel A, Strandness DE. Deep venous insufficiency: the relationship between lysis and subsequent reflux. J Vasc Surg 1993;18:596-608.
12. Rhodes JM, Cho JS, Gloviczki P, et al. Thrombolysis for experimental deep venous thrombosis maintains valvular competence and vasoreactivity. J Vasc Surg 2000;31:1193-1205.
13. Laiho MK, Oinonen A, Sugano N, Harjola VP, et al. Preservation of venous valve function after catheter-directed and systemic thrombolysis for deep venous thrombosis. Eur J Vasc Endovasc Surg 2004;28:391-396.
14. Elsharawy M, Elzayat E. Early results of thrombolysis vs anticoagulation in iliofemoral venous thrombosis: a randomised clinical trial. Eur J Vasc Endovasc Surg 2002;24:209-214.
15. Comerota AJ, Throm RC, Mathias SD, Haughton S, Mewissen M. Catheter-directed thrombolysis for ilio-femoral deep vein thrombosis improves health-related quality of life. J Vasc Surg 2000;32(1):130-137.
16. Schweizer J, Kirch W, Koch R, et al. Short- and long-term results after thrombolytic treatment of deep venous thrombosis. J Am Coll Cardiol 2000;36:1336-1343.
17. AbuRahma AF, Perkins SE, Wulu JT, Ng HK. Iliofemoral deep vein thrombosis: conventional therapy versus lysis and percutaneous transluminal angioplasty and stenting. Ann Surg 2001;233(6):752-760.
18. Wells PS, Forster AJ. Thrombolysis in deep vein thrombosis: is there still an indication? Thromb Haemost 2001;86:499-508.
19. Ouriel K, Gray B, Clair DG, et al. Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis. J Vasc Interv Radiol 2000;11:295-298.
20. Goldhaber SZ. Thrombolysis in venous thromboembolism: an international perspective. Chest 1990;97(4 suppl):176S-181S.
21. Buller HR, Agnelli G, Hull R, et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 suppl):401S-428S.
22. Vachani A, Arcasoy SM. Thrombolytic therapy for deep venous thrombosis: analysis of benefits and risks. Clin Pulm Med 2004;11:328-334.
23. Sharafuddin MJ, Sun S, Hoballah JJ, Youness FM, Sharp WJ, Roh BS. Endovascular management of venous thrombotic and occlusive diseases of the lower extremities. J Vasc Interv Radiol 2003;14:405-423.
24. Semba CP, Dake MD. Iliofemoral deep venous thrombosis: aggressive therapy with catheter-directed thrombolysis. Radiology 1994;191:487-494.
25. Bjarnason H, Kruse JR, Asinger DA, et al. Iliofemoral deep venous thrombosis: safety and efficacy outcome during 5 years of catheter-directed thrombolytic therapy. J Vasc Interv Radiol 1997;8:405-418.
26. Mewissen MW, Seabrook GR, Meissner MH, Cynamon J, Labropoulos N, Haughton SH. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry. Radiology 1999;211:39-49.
27. Chang R, Horne MK 3rd, Mayo DJ, Doppman JL. Pulse-spray treatment of subclavian and jugular venous thrombi with recombinant tissue plasminogen activator. J Vasc Interv Radiol 1996;7:845-851.
28. Chang R, Cannon RO 3rd, Chen CC, et al. Daily catheter-directed single dosing of r-tPA in treatment of acute deep vein thrombosis of the lower extremity. J Vasc Interv Radiol 2001;12(2):247-252.
29. Bookstein JJ, Valji K. Pulse-spray pharmacomechanical thrombolysis. Cardiovasc Intervent Radiol 1992;15:228-233.
30. Horne MK 3rd, Chang R. Pharmacokinetics of pulse-sprayed recombinant tissue plasminogen activator for deep venous thrombosis. Thromb Res 2003;111:111-114.
31. Vedantham S, Grassi CJ, Ferral H, et al. Reporting standards for endovascular treatment of lower extremity deep vein thrombosis. J Vasc Interv Radiol 2006;17:417-434.
32. Marder VJ, Soulen RL, Atichartakarn V, et al. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 1977;89:1018-1029.
33. Priest DL, Zweibel WJ. Chronic venous insufficiency, varicose veins, and saphenous vein mapping. In: Zweibel WJ, ed. Introduction to vascular ultrasonography. 3rd ed. Philadelphia, Pa: Saunders, 1992; 326.
34. Evans CJ, Allan PL, Lee AJ, et al. Prevalence of venous reflux in the general population on duplex scanning: the Edinburgh vein study. J Vasc Surg 1998;28:767-776.
35. Labropoulos N, Tiogson J, Pryor L, et al. Definition of venous reflux in the lower extremity veins. J Vasc Surg 2003;38:793-798.
36. Horne MK 3rd, Mayo DJ, Cannon RO, et al. Intraclot recombinant tissue plasminogen activator in the treatment of deep venous thrombosis of the lower and upper extremities. Am J Med 2000;108(3):251-255.
37. Ouriel K, Katzen B, Mewissen MW, et al. Reteplase in the treatment of peripheral arterial and venous occlusion: a pilot study. J Vasc Interv Radiol 2000;11(7):849-854.
38. Castaneda F, Li R, Young K, et al. Catheter-directed thrombolysis in deep vein thrombosis with use of reteplase: intermediate results and complications of a pilot study. J Vasc Interv Radiol 2002;13(6):577-580.
39. Razavi MK, Wong H, Kee ST, Sze DY, Semba CP, Dake MD. Initial clinical results of tenecteplase (TNK) in catheter-directed thrombolytic therapy. J Endovasc Ther 2002;9:593-598.
40. Agnelli G, Buchanan MR, Fernandez F, Hirsh J. The thrombolytic and hemorrhagic effects of tissue type plasminogen activator: influence of dosage regimens in rabbits. Thromb Res 1985;40:769-777.
41. Agnelli G, Buchanan MR, Fernandez F, Van Ryn J, Hirsh J. Sustained thrombolysis with DNA-recombinant tissue type plasminogen activator in rabbits. Blood 1985;66:399-401.
42. Agnelli G. Rationale for bolus t-PA therapy to improve efficacy and safety. Chest 1990;97(4 suppl):161S-167S.
43. Williams AF. The formation of the popliteal vein. Surg Gynecol Obstet 1953;97:769-772.
44. Quinlan DJ, Alikhan R, Gishen P, Sidhu PS. Variations in lower limb venous anatomy: implications for US diagnosis of deep venous thrombosis. Radiology 2003;228:443-448.
45. May R. Anatomy. In: Ebert PA, ed. Surgery of the veins of the leg and pelvis. Major problems in clinical surgery series. Vol XXIII. Translated by Hirsch H. Philadelphia, Pa: W.B. Saunders, 1979; 1-36.
46. Nicolaides AN, Kakkar VV, Field ES, Renney JT. The origin of deep vein thrombosis: a venographic study. Br J Radiol 1971;44:653-663.
47. Ouriel K, Green RM, Greenberg RK, Clair DG. The anatomy of deep venous thrombosis of the lower extremity. J Vasc Surg 2000;31(5):895-900.
48. Singh H, Masuda EM. Comparing short-term outcomes of femoral-popliteal and iliofemoral deep venous thrombosis: early lysis and development of reflux. Ann Vasc Surg 2005;19(1):74-79.
49. Christopoulos D, Nicolaides AN, Cook A, Irvine A, Galloway JM, Wilkinson A. Pathogenesis of venous ulceration in relation to the calf muscle pump function. Surgery 1989;106:829-835.
50. Torr SR, Nachowiak DA, Fujii S, Sobel BE. "Plasminogen steal" and clot lysis. J Am Coll Cardiol 1992;19:1085-1090.
51. Rijken DC, Sakharov DV. Basic principles in thrombolysis: regulatory role of plasminogen. Thromb Res 2001;103(suppl 1):S41-S49.
52. Wu JH, Diamond SL. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin: a mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen. J Clin Invest 1995;95:2483-2490.